National Academies Press: OpenBook
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1991. Expanding Access to Investigational Therapies for HIV Infection and AIDS. Washington, DC: The National Academies Press. doi: 10.17226/1778.
×

Expanding Access to Investigational Therapies for HIV Infection and AIDS

March 12–13, 1990 Conference Summary

Eve Nichols

Roundtable for the Development of Drugs and Vaccines Against AIDS

Institute of Medicine

NATIONAL ACADEMY PRESS
Washington, D.C. 1991

Suggested Citation:"FRONT MATTER." Institute of Medicine. 1991. Expanding Access to Investigational Therapies for HIV Infection and AIDS. Washington, DC: The National Academies Press. doi: 10.17226/1778.
×

National Academy Press
2101 Constitution Avenue, NW Washington, DC 20418

This conference summary was written by Eve Nichols for the Institute of Medicine's Roundtable for the Development of Drugs and Vaccines Against AIDS, chaired by Harold Ginsberg and Sheldon Wolff and directed by Robin Weiss. The document reports major themes of the conference discussions; these themes, however, do not represent policy statements by the Institute of Medicine.

The report has been reviewed by a group other than the authors according to procedures approved by a Report Review Committee consisting of members of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.

The Institute of Medicine was chartered in 1970 by the National Academy of Sciences to enlist distinguished members of appropriate professions in the examination of policy matters pertaining to the health of the public. In this, the Institute acts under both the Academy's 1863 congressional charter responsibility to be an advisor to the federal government, and its own initiative in identifying issues of medical care, research, and education.

The Roundtable is supported by the American Foundation for AIDS Research, the Merck Company Foundation, the Pharmaceutical Manufacturers Association, the U.S. Army, the U.S. Public Health Service, and the U.S. Department of Veterans Affairs.

Library of Congress Catalog Card No. 91-60585

International Standard Book Number 0-309-04490-1

Additional copies of this report are available from:
National Academy Press
2101 Constitution Avenue, NW Washington, DC 20418

S345

Printed in the United States of America

The serpent has been a symbol of long life, healing, and knowledge among almost all cultures and religions since the beginning of recorded history. The image adopted as a logotype by the Institute of Medicine is based on a relief carving from ancient Greece, now held by the Staatlichemuseen in Berlin.

Suggested Citation:"FRONT MATTER." Institute of Medicine. 1991. Expanding Access to Investigational Therapies for HIV Infection and AIDS. Washington, DC: The National Academies Press. doi: 10.17226/1778.
×

ROUNDTABLE FOR THE DEVELOPMENT OF DRUGS AND VACCINES AGAINST AIDS

HAROLD S. GINSBERG (Co-chair), Eugene Higgins Professor of Medicine and Microbiology,

Department of Medicine, College of Physicians & Surgeons, Columbia University, New York

SHELDON M. WOLFF (Co-chair), Physician-in-Chief,

New England Medical Center, and

Endicott Professor and Chairman,

Department of Medicine, Tufts University School of Medicine, Boston

DAVID W. BARRY, Vice President of Research,

The Wellcome Research Laboratories, Burroughs Wellcome Co., Research Triangle Park, North Carolina

JAMES S. BENSON, Acting Commissioner,

Food and Drug Administration, Rockville, Maryland

DONALD S. BURKE, Colonel,

Medical Corps, U.S. Army, and

Director,

Division of Retrovirology, Walter Reed Army Institute of Research, Rockville, Maryland

BRUCE A. CHABNER, Director,

Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

MAX D. COOPER, Investigator,

Howard Hughes Medical Institute, and

Professor of Medicine, Pediatrics, and Microbiology,

University of Alabama, Birmingham

MARTIN DELANEY, Co-Executive Director and President,

Project Inform, San Francisco

DANIEL DEYKIN, Chief,

Cooperative Studies Program. Veterans Administration Medical Center, Boston

R. GORDON DOUGLAS, Senior Vice President,

Medical and Scientific Affairs, Merck Sharp & Dohme International, Rahway, New Jersey

ANTHONY S. FAUCI, Associate Director for AIDS Research,

National Institutes of Health, and

Director,

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

GERALD FRIEDLAND, Professor of Medicine,

Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, The Bronx, New York

L. PATRICK GAGE, Executive Vice President,

Genetics Institute, Inc., Cambridge, Massachusetts

PETER BARTON HUTT, Partner,

Covington & Burling, Washington, D.C.

JAY C. LIPNER, Partner,

Silverstein Langer Lipner & Newburgh, New York, New York

Suggested Citation:"FRONT MATTER." Institute of Medicine. 1991. Expanding Access to Investigational Therapies for HIV Infection and AIDS. Washington, DC: The National Academies Press. doi: 10.17226/1778.
×

DAVID W. MARTIN, JR., Vice President,

Research and Development, The Dupont Merck Pharmaceutical Company, Wilmington, Delaware

CATHERINE M. WILFERT, Professor of Pediatrics and Microbiology,

Department of Pediatrics, Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina

STAFF

ROBIN WEISS, Project Director and Director,

AIDS Activities

SHARON BARATZ, Research Associate

RICHARD BERZON, Staff Officer

GAIL SPEARS, Administrative Assistant

Suggested Citation:"FRONT MATTER." Institute of Medicine. 1991. Expanding Access to Investigational Therapies for HIV Infection and AIDS. Washington, DC: The National Academies Press. doi: 10.17226/1778.
×

PREFACE

The Roundtable for the Development of Drugs and Vaccines Against AIDS was established in 1988 by the Institute of Medicine. Composed of leaders from government, the pharmaceutical industry, academia, and the public, its mission is to identify and help resolve impediments to the speedy availability of safe and effective drugs and vaccines for human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS). The Roundtable accomplishes its mission through regular meetings of its membership, during which urgent issues are identified and discussed, as well as through public conferences and workshops that explore scientific and policy matters central to the development of AIDS therapeutics. This publication is the report of a conference held March 12 and 13, 1990, in Washington, D.C.

The call for a "parallel track" for AIDS drug development—a proposal that would allow the early distribution of AIDS drugs to large numbers of patients in parallel with the conventional clinical trials that assess the drugs' safety and efficacy—has sparked controversy within the scientific community. Questions have arisen about the risks to patients of such a plan, about its potential effect on the successful completion of standard controlled trials, and about whether the parallel track will generate useful data. Larger questions have also been raised about whether the parallel track heralds fundamental changes in the philosophy underlying drug regulation in the United States, about the costs and financing of investigational therapies and associated medical costs, and about the role of expanded access mechanisms for drugs in reaching those whose health care generally is inadequate. The Roundtable sought to illuminate these issues by inviting knowledgeable speakers and the public to a two-day conference to examine proposals for expanded access to investigational drugs and possible repercussions of such an action.

Two months after the conference was held, in May 1990, the parallel track proposal was published in the Federal Register and comments were

Suggested Citation:"FRONT MATTER." Institute of Medicine. 1991. Expanding Access to Investigational Therapies for HIV Infection and AIDS. Washington, DC: The National Academies Press. doi: 10.17226/1778.
×

sought. A meeting was held in September 1990 by the Public Health Service (PHS) to discuss the comments. As this report goes to press, the PHS is finalizing the document, which, when completed, will constitute a written PHS policy. As the policy takes effect, many of the issues raised in this report will serve as valuable guideposts in evaluating the parallel track experiment.

A note on terminology: Although the word effectiveness rather than efficacy was used by Congress in the Drug Amendments of 1962, we have chosen in this report to conform to the definitions of the two terms as they are commonly understood in the field of medical technology assessment. Here, the term efficacy refers to what a method (e.g., a drug) can accomplish in expert hands when correctly applied to a patient; effectiveness refers to its performance in more general routine applications.1 Therefore, most randomized clinical trials assess efficacy; the Food and Drug Administration, in reviewing the results of these trials, is evaluating the efficacy of the drugs under investigation.

This report seeks to summarize the conference presentations. It contains no recommendations or conclusions, and the Roundtable has neither altered nor commented on the views and opinions expressed by the speakers, except for purposes of clarity. The Roundtable and staff wish to thank Eve Nichols, whose capable hands crafted the transcript of the meeting into a smooth narrative. We also thank, once again, the conference speakers for their thoughtful presentations, and all participants for the lively and challenging discussions throughout the conference.

1  

Institute of Medicine, Assessing Medical Technologies (Washington, D.C.: National Academy Press, 1985).

Suggested Citation:"FRONT MATTER." Institute of Medicine. 1991. Expanding Access to Investigational Therapies for HIV Infection and AIDS. Washington, DC: The National Academies Press. doi: 10.17226/1778.
×
Page viii Cite
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1991. Expanding Access to Investigational Therapies for HIV Infection and AIDS. Washington, DC: The National Academies Press. doi: 10.17226/1778.
×
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1991. Expanding Access to Investigational Therapies for HIV Infection and AIDS. Washington, DC: The National Academies Press. doi: 10.17226/1778.
×

EXPANDING ACCESS TO INVESTIGATIONAL THERAPIES FOR HIV INFECTION AND AIDS

Suggested Citation:"FRONT MATTER." Institute of Medicine. 1991. Expanding Access to Investigational Therapies for HIV Infection and AIDS. Washington, DC: The National Academies Press. doi: 10.17226/1778.
×
This page in the original is blank.
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1991. Expanding Access to Investigational Therapies for HIV Infection and AIDS. Washington, DC: The National Academies Press. doi: 10.17226/1778.
×
Page R1
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1991. Expanding Access to Investigational Therapies for HIV Infection and AIDS. Washington, DC: The National Academies Press. doi: 10.17226/1778.
×
Page R2
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1991. Expanding Access to Investigational Therapies for HIV Infection and AIDS. Washington, DC: The National Academies Press. doi: 10.17226/1778.
×
Page R3
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1991. Expanding Access to Investigational Therapies for HIV Infection and AIDS. Washington, DC: The National Academies Press. doi: 10.17226/1778.
×
Page R4
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1991. Expanding Access to Investigational Therapies for HIV Infection and AIDS. Washington, DC: The National Academies Press. doi: 10.17226/1778.
×
Page R5
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1991. Expanding Access to Investigational Therapies for HIV Infection and AIDS. Washington, DC: The National Academies Press. doi: 10.17226/1778.
×
Page R6
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1991. Expanding Access to Investigational Therapies for HIV Infection and AIDS. Washington, DC: The National Academies Press. doi: 10.17226/1778.
×
Page R7
Page viii Cite
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1991. Expanding Access to Investigational Therapies for HIV Infection and AIDS. Washington, DC: The National Academies Press. doi: 10.17226/1778.
×
Page R8
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1991. Expanding Access to Investigational Therapies for HIV Infection and AIDS. Washington, DC: The National Academies Press. doi: 10.17226/1778.
×
Page R9
Suggested Citation:"FRONT MATTER." Institute of Medicine. 1991. Expanding Access to Investigational Therapies for HIV Infection and AIDS. Washington, DC: The National Academies Press. doi: 10.17226/1778.
×
Page R10
Next: CONFERENCE PROGRAM »
Expanding Access to Investigational Therapies for HIV Infection and AIDS Get This Book
×
Buy Paperback | $40.00
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The call for a "parallel track" for AIDS drug development—a proposal that would allow the early distribution of AIDS drugs to large numbers of patients in parallel with the conventional clinical trials that assess the drugs' safety and efficacy—has sparked controversy within the scientific community. Questions have arisen about the risks to patients of such a plan, about its potential effect on the successful completion of standard controlled trials, and about whether the parallel track will generate useful data.

Larger questions have also been raised about whether the parallel track heralds fundamental changes in the philosophy underlying drug regulation in the United States, about the costs and financing of investigational therapies and associated medical costs, and about the role of expanded access mechanisms for drugs in reaching those whose health care is generally inadequate. This volume summarizes a conference hosted by the Institute of Medicine that illuminated these issues.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!